TABLE 1.
List of the new agents for difficult-to-treat resistant Gram-negatives.†
| Antibiotic | ESBL | KPC | OXA-48 | MBL | CRPA | CRAB |
|---|---|---|---|---|---|---|
| β-lactam/β-lactamase inhibitors | ||||||
| Meropenem/vaborbactam | ✓ | ✓ | - | - | - | - |
| Meropenem/nacubactam | ✓ | ✓ | ✓ | - | - | - |
| Meropenem/QPX7728 | ✓ | ✓ | ✓ | ✓ | ± | ✓ |
| Imipenem/relebactam | ✓ | ✓ | - | - | ✓ | - |
| Ceftazidime/avibactam† | ✓ | ✓ | ✓ | - | ✓ | - |
| Ceftolozane/tazobactam† | ✓ | - | - | - | ✓ | - |
| Cefepime/tazobactam | ✓ | - | ✓ | - | - | - |
| Cefepime/enmetazobactam | ✓ | - | - | - | - | - |
| Cefepime/zidebactam | ✓ | ✓ | ✓ | ✓ | ± | ± |
| Cefepime/VNRX5133 | ✓ | ✓ | ✓ | ± | ± | - |
| Cefepime/QPX7728 | ✓ | ✓ | ✓ | ✓ | ± | - |
| Ceftibuten/VNRX-7145 | ✓ | - | - | - | - | - |
| Ceftibuten/QPX7728 | ✓ | ✓ | ✓ | - | - | - |
| Cefpodoxime/ETX-0282 | ✓ | - | - | - | - | - |
| Aztreonam/avibactam | ✓ | ✓ | ✓ | ✓ | - | - |
| Sulbactam/durlobactam | ✓ | ✓ | ✓ | ✓ | - | ✓ |
| β-lactams | ||||||
| Cefiderocol | ✓ | ✓ | ✓ | ± | ✓ | ± |
| Tebipenem | ✓ | - | - | - | - | - |
| Sulopenem | ✓ | - | - | - | - | - |
| Aminoglycosides | ||||||
| Plazomicin | ✓ | ✓ | ✓ | ± | - | - |
| Tetracyclines | ||||||
| Eravacycline | ✓ | ✓ | ✓ | ✓ | - | ± |
| Polymyxins | ||||||
| SPR741 plus β-lactams | ✓ | ±‡ | ±‡ | - | - | ✓ |
| SPR206 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| QPX9003 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Source: Paterson DL, Isler B, Stewart A. New treatment options for multiresistant gram negatives. Curr Opin Infect Dis. 2020;33(2):214–223. https://doi.org/10.1097/QCO.0000000000000627
ESBL, extended spectrum β-lactamases; KPC, Klebsiella pneumoniae carbapenemase; OXA-48, Oxacillinase-48; MBL, Metallo-beta-lactamases; CRPA, Carbapenem-resistant Pseudomonas aeruginosa; CRAB, Carbapenem-resistant Acinetobacter baumannii.
†
, Only ceftazidime-avibactam and ceftolozane-tazobactam are registered in South Africa.
‡
, Active against Escherichia coli, inactive against Klebsiella pneumoniae.